If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
16.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.50 (3.226%)
Market Cap: £13.20m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Directors' Shareholdings

23 Dec 2025 14:17

RNS Number : 7107M
Frontier IP Group plc
23 December 2025
 

23 December 2025

 

Frontier IP Group plc

("Frontier IP", the "Company" or the "Group")

 

Directors' Shareholdings

 

Frontier IP Group plc (AIM: FIPP), a specialist in commercialising intellectual property, confirms that, further to the announcement released on 22 December 2025 on the closing of the Retail Offer, the shareholdings of the Directors following their participation in the Subscription and the completion of the Fundraising are as follows:

Director

 

Total number of Ordinary Shares held

Percentage of enlarged share capital following the Retail Offer Admission (%)

Neil Crabb (Chief Executive Officer)

4,576,018

6.05

Nigel Grierson (Non-Executive Director)

135,946

0.18

Professor Dame Julia King (Non-Executive Chair)

679,724

0.90

Jacqueline McKay (Chief Operating Officer)

368,039

0.49

Joanne Stent (Chief Financial Officer)

60,023

0.08

Matthew White (Chief Commercialisation Officer)

121,545

0.16

David Holbrook (Non-Executive Director)

13,595

0.02

 

The FCA notification table in respect of these Director dealings, made in accordance with the requirements of UK MAR, is appended further below.

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the launch announcement released by the Company on 17 December 2025.

ENQUIRIES

 

Frontier IP Group Plc

Neil Crabb, Chief Executive

 

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

 neil@frontierip.co.uk

 

M: 07464 546 025

andrew.johnson@frontierip.co.uk

 

Allenby Capital Limited (Nominated Adviser)

Nick Athanas

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Charles Leigh-Pemberton / James Fischer

T: 0207 496 3000

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated (PCA)

a)

Name

Neil Crabb

Chief Executive Officer

Nigel Grierson

Non-Executive Director

Professor Dame Julia King

Non-Executive Chair

Jacqueline McKay

Chief Operating Officer

Joanne Stent

Chief Financial Officer

Matthew White

Chief Commercialisation Officer

David Holbrook

Non-Executive Director

 

 

 

2

Reason for the notification

a)

Position/status

See 1a) above

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Frontier IP Group plc

b)

LEI

213800BRYUKQPJWKJ312

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 10p each in Frontier IP Group Plc

Identification code (ISIN) for Frontier IP Group Plc ordinary shares: GB00B63PS212

b)

Nature of the transaction

Fundraising for New Ordinary Shares

 

c)

Price(s) and volume(s)

Price: 15.5 pence

 

Volumes:

 

Neil Crabb

645,162

Nigel Grierson

64,517

Professor Dame Julia King

322,581

Jacqueline McKay

51,613

Joanne Stent

6,452

Matthew White

32,259

David Holbrook

6,452

 

d)

Aggregated information

- Aggregated volume

- Price

N/A

 

e)

Date of the transaction

22 December 2025

f)

Place of the transaction

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUOASRVSUUUAA
Date   Source Headline
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSUnaudited Half Year Results
24th Mar 20257:00 amRNSCamGraphIC secures €25 million in Series A funding
18th Mar 20257:00 amRNS-RPulsiv wins PSMA’s Global Energy Efficiency Award
25th Feb 20257:00 amRNS-RGraphEnergyTech collaboration & Innovate UK grant
18th Feb 20257:00 amRNS-RTopps Tiles launches Alusid’s Mas floor tiles
31st Dec 20241:30 pmRNSTotal Voting Rights
30th Dec 20249:56 amRNSHolding(s) in Company
20th Dec 20247:00 amRNSGrant of Options
19th Dec 20244:14 pmRNSResult of AGM
29th Nov 20245:00 pmRNSTotal Voting Rights
29th Nov 20241:36 pmRNSHolding(s) in Company
27th Nov 20247:00 amRNSPosting of Circular & Annual Report, & AGM Notice
26th Nov 20247:00 amRNSResult of Retail Offer
22nd Nov 20241:31 pmRNSResult of Placing and Subscription
22nd Nov 20248:12 amRNSRetail Offer by PrimaryBid
22nd Nov 20247:01 amRNSProposed Placing and Subscription
22nd Nov 20247:00 amRNSFinal results for the year ended 30 June 2024
29th Oct 20244:45 pmRNSHolding(s) in Company
11th Sep 202412:10 pmRNSHolding(s) in Company
7th Aug 20243:52 pmRNSHolding(s) in Company
6th Aug 20243:47 pmRNSHolding(s) in Company
28th Jun 20247:00 amRNSPortfolio – Cambridge Raman Imaging loan facility
19th Jun 20247:00 amRNSHolding(s) in Company
24th May 20247:00 amRNSTopps Group’s arm launches Alusid floor tile range
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.